Michael E. Lewis, Ph.D.
Chief Scientific Advisor
Dr. Lewis, one of our founders, has had over 30 years of experience in the biopharmaceutical industry, and prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan. Previously, Dr. Lewis received training in psychobiology research at the National Institute of Mental Health and at Clark University, where he received a Ph.D. in psychology, and then received postdoctoral training in psychopharmacology and neuropharmacology at the University of Cambridge. After establishing and directing a molecular neuropharmacology laboratory at DuPont, Dr. Lewis co-founded Cephalon, Inc. (Nasdaq; CEPH), serving as Director of Pharmacology and Senior Director of Scientific Affairs. Dr. Lewis later co-founded and served as Chief Scientific Advisor to Adolor Corporation (Nasdaq; ADLR), and was subsequently invited by Dr. Chalmers to co-found Arena Pharmaceuticals (Nasdaq; ARNA), where he served as a pre-IPO Director and Chief Scientific Advisor. Dr. Lewis is an inventor or co-inventor on 17 issued U.S. patents and is an author or co-author of numerous scientific papers, including over 40 publications on opioids and opioid receptors.